Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Aug 6, 2026, 04:58Shamee Shastry: Advancing Precision in Massive Bleed Management
-
Aug 6, 2026, 01:21Orly Leiva: High-Output Heart Failure Signals Disease Progression in PV and ET
-
Aug 5, 2026, 23:46Recommended ESC Congress Sessions for the ESC Working Group on Thrombosis
-
Aug 5, 2026, 23:36Heghine Khachatryan: ISTH Day 2 – Phase III VAYHIT2 Data Highlights Ianalumab in Primary ITP
-
Aug 5, 2026, 23:28Basyouni Omran: KDIGO 2025/2026 Bedside Guide – Iron Correction in CKD
-
Aug 5, 2026, 23:13C. Michael Gibson: Jean Connors on Antithrombotic Therapy for LVAD at Baim Grand Rounds
-
Aug 5, 2026, 23:07Building Safer Systems for Bleeding and Clotting Care with Dr. Toyosi Onwuemene
-
Aug 5, 2026, 21:19Vidhi Shukla: Anticoagulant Activity of Ficus Racemosa Bark Extract in Rats
-
Aug 5, 2026, 20:30Denis Oduor: Patient Blood Management and Systemic Transfusion Reform